Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Tabletop particle accelerator could transform medicine and materials science 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Many companies are already undergoing trials for a possible cure to the ongoing COVID-19 pandemic. Aside from the developments made by Pfizer and Moderna in developing their respective vaccines, another pharmaceutical company has made progress.
UK pharmaceutical firm AstraZeneca has developed a COVID-19 antibody cocktail that can potentially protect the person from infection for up to 12 months. The drug, known as AZD7442, makes use of a different process in helping the body fight the virus compared to a regular vaccine. Late-stage trials of the drug are already underway and the firm has started recruiting international clinical trials involving 5,000 from both Europe and the United States.
AZD7442 relies on the prophylactic process which involves introducing new antibodies into the body to fight the disease instead of triggering the body to create them. The drug acts with monoclonal antibodies that mimic the body’s natural antibodies and this process has already been used to treat cancer patients. This will especially be beneficial for those with weak immune systems compared to simply being vaccines as their bodies have already been compromised from creating new antibodies. The trials began over the weekend in the UK, involving 1,000 participants in nine sites.
The firm announced that this antibody cocktail can potentially treat patients or be taken as a preventative medication especially to healthcare workers at the front lines. “These have been engineered specifically to have what we call a long half-life, so we think they can confer protection for at least six, but more likely closer to 12 months,” said the company’s executive vice president of biopharmaceuticals research and development Mene Pangalos.
As the world waits for vaccines and a cure for COVID-19, people are highly advised to adhere to public health and safety guidelines to slow the spread of the coronavirus. Video streaming platform YouTube recently clamped down on the right-wing media organization OANN from posting videos and live streaming for a week, after the organization shared a fake cure for the disease.
Aside from restricting uploads, YouTube has also demonetized the channel, citing that the OANN has repeatedly violated its misinformation guidelines especially related to COVID-19.
